Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant

被引:36
作者
Nojima, J [1 ]
Suehisa, E [1 ]
Akita, N [1 ]
Toku, M [1 ]
Fushimi, R [1 ]
Tada, H [1 ]
Kuratsune, H [1 ]
Machii, T [1 ]
Kitani, T [1 ]
Amino, N [1 ]
机构
[1] OSAKA UNIV, SCH MED, DEPT LAB MED, SUITA, OSAKA 565, JAPAN
关键词
anticardiolipin antibodies; lupus anticoagulant; beta 2-glycoprotein I; thrombosis; antiphospholipid syndrome;
D O I
10.1046/j.1365-2141.1997.d01-2055.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The relationship between arterial or venous thrombosis and the levels of anticardiolipin antibodies (aCL) and/or existence of lupus anticoagulant (LA) was studied. The 141 patients with systemic lupus erythematosus (SLE) were divided into four groups: aCL single positive (25 cases), LA single positive (11 cases), aCL and LA double positive (25 cases), aCL and LA double negative (80 cases). The prevalence of thrombosis was higher in aCL and LA double positive patients (21/25 cases, 84.0%, P < 0.01) than that in aCL single positive patients (4/25 cases, 16.0%), LA single positive patients (1/11 cases, 9.1%) and double negative patients (3/80 cases, 3.8%), Furthermore, in these double positive patients, all patients (10/10 cases) with a high positive level of aCL (> 10 units/ml) had arterial thrombosis, whereas only 2/15 patients (13.3%) with a low positive level of aCL (3-10 units/ml) were affected, Venous thrombosis was frequently found in the low positive group (9/15 cases, 60.0%). On the contrary, none of 105 LA negative patients had arterial thrombosis and only seven (6.7%) had venous thrombosis. These findings indicate that a high aCL activity combined with a LA positive result might be a risk factor for arterial thrombosis.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 26 条
[1]  
BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629
[2]  
BEVERS EM, 1990, LANCET, V336, P952
[3]   LUPUS ANTICOAGULANT AND INCREASED THROMBIN GENERATION IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FERRO, D ;
QUINTARELLI, C ;
VALESINI, G ;
VIOLI, F .
BLOOD, 1994, 83 (01) :304-304
[4]   ANTICARDIOLIPIN ANTIBODIES (ACA) DIRECTED NOT TO CARDIOLIPIN BUT TO A PLASMA-PROTEIN COFACTOR [J].
GALLI, M ;
COMFURIUS, P ;
MAASSEN, C ;
HEMKER, HC ;
DEBAETS, MH ;
VANBREDAVRIESMAN, PJC ;
BARBUI, T ;
ZWAAL, RFA ;
BEVERS, EM .
LANCET, 1990, 335 (8705) :1544-1547
[5]   ANTICARDIOLIPIN ANTIBODIES - ISOTYPE DISTRIBUTION AND PHOSPHOLIPID SPECIFICITY [J].
GHARAVI, AE ;
HARRIS, EN ;
ASHERSON, RA ;
HUGHES, GRV .
ANNALS OF THE RHEUMATIC DISEASES, 1987, 46 (01) :1-6
[6]   ANTIPHOSPHOLIPID ANTIBODIES (APL) IN SYSTEMIC LUPUS-ERYTHEMATOSUS - ARE THEY SPECIFIC TOOLS FOR THE DIAGNOSIS OF APL SYNDROME [J].
GHIRARDELLO, A ;
DORIA, A ;
RUFFATTI, A ;
RIGOLI, AM ;
VESCO, P ;
CALLIGARO, A ;
GAMBARI, PF .
ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (02) :140-142
[7]  
HARRIS EN, 1983, LANCET, V2, P1211
[8]   THROMBOSIS, RECURRENT FETAL LOSS, AND THROMBOCYTOPENIA - PREDICTIVE VALUE OF THE ANTICARDIOLIPIN ANTIBODY-TEST [J].
HARRIS, EN ;
CHAN, JKH ;
ASHERSON, RA ;
ABER, VR ;
GHARAVI, AE ;
HUGHES, GRV .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (11) :2153-2156
[9]  
HUGHES GRV, 1986, J RHEUMATOL, V13, P486
[10]   THE ANTIPHOSPHOLIPID SYNDROME - 10 YEARS ON [J].
HUGHES, GRV .
LANCET, 1993, 342 (8867) :341-344